155 related articles for article (PubMed ID: 27082957)
1. Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases.
Schupp JC; Köhler T; Müller-Quernheim J
Respiration; 2016; 91(4):296-301. PubMed ID: 27082957
[TBL] [Abstract][Full Text] [Related]
2. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
3. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia.
Corte TJ; Ellis R; Renzoni EA; Hansell DM; Nicholson AG; du Bois RM; Wells AU
Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(2):132-8. PubMed ID: 20560293
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
Tochimoto A; Kawaguchi Y; Hara M; Tateishi M; Fukasawa C; Takagi K; Nishimagi E; Ota Y; Katsumata Y; Gono T; Tanaka E; Yamanaka H
Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for systemic sclerosis related interstitial lung diseases.
Mouthon L; Bérezné A; Guillevin L; Valeyre D
Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.
Kondoh Y; Taniguchi H; Yokoi T; Nishiyama O; Ohishi T; Kato T; Suzuki K; Suzuki R
Eur Respir J; 2005 Mar; 25(3):528-33. PubMed ID: 15738299
[TBL] [Abstract][Full Text] [Related]
7. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide.
Abhishek A; Yazdani R; Pearce F; Regan M; Lim K; Hubbard R; Lanyon P
Clin Rheumatol; 2011 Aug; 30(8):1099-104. PubMed ID: 21484227
[TBL] [Abstract][Full Text] [Related]
8. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
[TBL] [Abstract][Full Text] [Related]
9. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases.
Okada M; Suzuki K; Matsumoto M; Nakashima M; Nakanishi T; Takada K; Horikoshi H; Matsubara O; Ohsuzu F
Mod Rheumatol; 2007; 17(2):131-6. PubMed ID: 17437168
[TBL] [Abstract][Full Text] [Related]
10. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases.
Schnabel A; Reuter M; Gross WL
Arthritis Rheum; 1998 Jul; 41(7):1215-20. PubMed ID: 9663478
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases.
Schulze AB; Evers G; Kümmel A; Rosenow F; Sackarnd J; Hering JP; Schülke C; Engelbertz JA; Görlich D; Barth PJ; Lenz G; Becker H; Mohr M; Schmidt LH
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(2):157-166. PubMed ID: 32476949
[TBL] [Abstract][Full Text] [Related]
13. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Solomon JJ; Ryu JH; Tazelaar HD; Myers JL; Tuder R; Cool CD; Curran-Everett D; Fischer A; Swigris JJ; Brown KK
Respir Med; 2013 Aug; 107(8):1247-52. PubMed ID: 23791462
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
van Gemert JP; van den Berk IAH; Nossent EJ; Heunks LMA; Jonkers RE; Vlaar AP; Bonta PI
BMC Pulm Med; 2021 Jul; 21(1):249. PubMed ID: 34320981
[TBL] [Abstract][Full Text] [Related]
15. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
16. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
17. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
18. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
20. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.
Schnabel A; Reuter M; Biederer J; Richter C; Gross WL
Semin Arthritis Rheum; 2003 Apr; 32(5):273-84. PubMed ID: 12701038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
